Cargando la página…

Fedratinib

Inrebic

100MG BASE capsuleEstados UnidosComercializadoAutorizado el 16 ago 2019

Contenido en inglés

Indicaciones

INREBIC ® is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF). INREBIC is a kinase inhibitor indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) ( 1 ).

Contraindicaciones

None None

Advertencias y precauciones

Anemia and Thrombocytopenia: Manage by dose reduction, interruption, or transfusion ( 5.2 ).
Gastrointestinal Toxicity: Manage by dose reduction or interruption if patient develops severe diarrhea, nausea, or vomiting. Prophylaxis with antiemetics and treatment with antidiarrhea medications are recommended ( 5.3 ).
Hepatic Toxicity: Manage by dose reduction or interruption ( 5.4 ).
Amylase and Lipase Elevation: Manage by dose reduction or interruption ( 5.5 ).
Uveitis: Monitor for symptoms and refer for ophthalmological evaluation ( 5.6 ).
Major Adverse Cardiac Events (MACE): Monitor for development of MACE ( 5.7 ).
Thrombosis: Evaluate and treat symptoms of thrombosis promptly ( 5.8 ).
Secondary Malignancies: Monitor for development of secondary malignancies, particularly in patients who are current or past smokers ( 5.9 ).
Symptom Exacerbation Following Interruption or Discontinuation of Treatment: Manage with supportive care and consider resuming treatment with INREBIC ( 5.10 ).

5.1Encephalopathy, Including Wernicke's Serious

and fatal encephalopathy, including Wernicke's encephalopathy, has occurred in INREBIC-treated patients. Serious cases were reported in 1.3% (8/608) of patients treated with INREBIC in clinical trials and 0.16% (1/608) of cases were fatal. Wernicke's encephalopathy is a neurologic emergency resulting from thiamine (Vitamin B1) deficiency. Signs and symptoms of Wernicke's encephalopathy may include ataxia, mental status changes, and ophthalmoplegia (e.g., nystagmus, diplopia).

¿Dos medicamentos en una misma pregunta?

Menciona dos o más medicamentos y Osler comprueba sus interacciones. Una interacción grave aparece al principio de la respuesta.

Descubre Osler

Fedratinib

Inrebic

100MG BASE capsuleEstados UnidosComercializadoAutorizado el 16 ago 2019

Contenido en inglés

Abrir en el registroPregúntale a Osler

Indicaciones

Contraindicaciones

None None

Advertencias y precauciones

Anemia and Thrombocytopenia: Manage by dose reduction, interruption, or transfusion ( 5.2 ).
Gastrointestinal Toxicity: Manage by dose reduction or interruption if patient develops severe diarrhea, nausea, or vomiting. Prophylaxis with antiemetics and treatment with antidiarrhea medications are recommended ( 5.3 ).
Hepatic Toxicity: Manage by dose reduction or interruption ( 5.4 ).
Amylase and Lipase Elevation: Manage by dose reduction or interruption ( 5.5 ).
Uveitis: Monitor for symptoms and refer for ophthalmological evaluation ( 5.6 ).
Major Adverse Cardiac Events (MACE): Monitor for development of MACE ( 5.7 ).
Thrombosis: Evaluate and treat symptoms of thrombosis promptly ( 5.8 ).
Secondary Malignancies: Monitor for development of secondary malignancies, particularly in patients who are current or past smokers ( 5.9 ).
Symptom Exacerbation Following Interruption or Discontinuation of Treatment: Manage with supportive care and consider resuming treatment with INREBIC ( 5.10 ).

5.1Encephalopathy, Including Wernicke's Serious

¿Dos medicamentos en una misma pregunta?

Menciona dos o más medicamentos y Osler comprueba sus interacciones. Una interacción grave aparece al principio de la respuesta.

Descubre Osler

Interacciones

Strong CYP3A4 Inhibitors: Reduce INREBIC dose as recommended ( 2.3 , 7.1 ).
Strong and Moderate CYP3A4 Inducers: Avoid use of INREBIC ( 7.1 ).
CYP3A4, CYP2C19, or CYP2D6 Substrates: Dose modifications of substrates drugs may be needed ( 7.2 ).
OCT2 and MATE1/2-K Substrates: Dose modifications of substrate drugs may be needed ( 7.2 ).

7.1Effect of Other Drugs on

INREBIC Strong CYP3A4 Inhibitors Coadministration of INREBIC with a strong CYP3A4 inhibitor increases fedratinib exposure [see Clinical Pharmacology (12.3) ] . Increased exposure may increase the risk of adverse reactions. Consider alternative therapies that do not strongly inhibit CYP3A4 activity. Alternatively, reduce the dose of INREBIC when administering with a strong CYP3A4 inhibitor [see Dosage and Administration (2.4) ] .

Strong and Moderate CYP3A4 Inducers Coadministration of INREBIC with a strong or moderate CYP3A4 inducer can decrease fedratinib exposure [see Clinical Pharmacology (12.3) ] . Decreased exposure may reduce the effectiveness of INREBIC. Avoid INREBIC with strong and moderate CYP3A4 inducers. Dual CYP3A4 and CYP2C19 Inhibitors Coadministration of INREBIC with a dual CYP3A4 and CYP2C19 inhibitor increases fedratinib exposure [see Clinical Pharmacology (12.3) ] .

Increased exposure may increase the risk of adverse reactions. Due to potential increase of exposure, patients taking concomitant dual CYP3A4 and CYP2C19 inhibitors require more intensive safety monitoring and, if necessary, dose modifications of INREBIC based on adverse reactions [see Dosage and Administration (2.6) ] .

7.2Effect of

INREBIC on Other Drugs CYP3A4, CYP2C19, or CYP2D6 Substrate Drugs Coadministration of INREBIC with drugs that are CYP3A4 substrates, CYP2C19 substrates, or CYP2D6 substrates increases the concentrations of these drugs, which may increase the risk of adverse reactions of these drugs [see Clinical Pharmacology (12.3) ] . Monitor for adverse reactions and adjust the dose of drugs that are CYP3A4, CYP2C19, or CYP2D6 substrates as necessary when coadministered with INREBIC.

OCT2 and MATE1/2-K Substrate Drugs Coadministration of INREBIC with drugs that are renally excreted via organic cation transporter (OCT2) and multidrug and toxin extrusion (MATE)1/2-K can decrease renal clearance of those drugs [see Clinical Pharmacology (12.3) ] . Monitor for adverse reactions and consider dose modifications for drugs that are renally excreted via OCT2 or MATE1/2-K (e.g., metformin), as necessary when coadministered with INREBIC.

Embarazo y lactancia

8.1Pregnancy Risk Summary

There are no available data on INREBIC use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, oral administration of fedratinib to pregnant rats during organogenesis at doses considerably lower than the recommended human daily dose of 400 mg/day resulted in adverse developmental outcomes (see Data ) . Consider the benefits and risks of INREBIC for the mother and possible risks to the fetus when prescribing INREBIC to a pregnant woman.

The background risk of major birth defects and miscarriage for the indicated population is unknown. Adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data In an embryo-fetal development study in pregnant rats, fedratinib administration at a dose of 30 mg/kg/day during organogenesis (gestation days 6 to 17) was associated with adverse developmental outcomes including skeletal variations (such as additional ossification center of neuronal arches).

These effects occurred in rats at approximately 0.1 times the clinical exposure based on AUC at the recommended daily dose. At lower doses of 10 mg/kg/day (0.01 times the clinical exposure at the recommended daily dose), fedratinib administered to pregnant rats resulted in maternal toxicity of decreased gestational weight gain. In an embryo-fetal development study in pregnant rabbits, fedratinib administration during organogenesis (gestation Days 6 to 18) did not produce developmental or maternal toxicity at doses up to the highest dose level tested, 30 mg/kg/day (approximately 0.08 times the clinical exposure at the recommended daily dose).

In a separate study, administration of 80 mg/kg/day fedratinib to rabbits resulted in maternal mortality. In a pre- and postnatal study in rats, fedratinib was administered to pregnant female rats at doses of 3, 10, or 30 mg/kg/day from Day 6 of gestation through Day 20 of lactation, with weaning on Day 21. A slight decrease in maternal body weight gain during gestation occurred at 30 mg/kg/day. The offspring from the high dose (30 mg/kg) had decreased body weight preweaning in both sexes and postweaning through the maturation phase in males.

These effects occurred at exposures approximately 0.1 times the clinical exposure at the recommended daily dose.

Reacciones adversas

The following clinically significant adverse reactions are described elsewhere in the labeling:

Encephalopathy, including Wernicke's [see Warnings and Precautions (5.1) ]
Anemia and Thrombocytopenia [see Warnings and Precautions (5.2) ]
Gastrointestinal Toxicity [see Warnings and Precautions (5.3) ]
Hepatic Toxicity [see Warnings and Precautions (5.4) ]
Amylase and Lipase Elevation [see Warnings and Precautions (5.5) ]
Uveitis [see Warnings and Precautions (5.6) ]
Major Adverse Cardiac Events [see Warnings and Precautions (5.7) ]
Thrombosis [see Warnings and Precautions (5.8) ]
Secondary Malignancies [see Warnings and Precautions (5.9) ]
Symptom Exacerbation Following Interruption or Discontinuation of Treatment [see Warnings and Precautions (5.10) ] The most common adverse reactions (≥20%) are diarrhea, nausea, anemia, and vomiting ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers Squibb at 1-800-721-5072 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data in the WARNINGS AND PRECAUTIONS Section

5.1 Encephalopathy, including Wernicke's, reflect exposure to INREBIC as a single agent in 608 patients who received more than one dose (ranging from 30 mg to 800 mg) in Studies JAKARTA, ARD11936, JAKARTA2, ARD12042, ARD12888, TED12037/TED12015, INT12497, and TES13519, of whom 459 were patients with myelofibrosis, including 97 patients previously treated with ruxolitinib. Among the 608 patients receiving INREBIC, the median drug exposure was 37 weeks and the median number of cycles initiated was 9 cycles.

Fifty-nine percent of 608 patients were exposed for 6 months or longer and 39% were exposed for 12 months or longer. Using the dataset described above, the most common adverse reactions in >20% of patients (N=608) were diarrhea, nausea, anemia, vomiting, fatigue, thrombocytopenia, and constipation. JAKARTA Trial The safety of INREBIC was evaluated in the randomized treatment period of the JAKARTA trial [see Clinical Studies (14) ] .

Key eligibility criteria included adult patients with intermediate-2 or high-risk primary MF or post-PV MF or post-ET MF with splenomegaly, platelet count ≥50 × 10 9 /L, and no splenectomy. Patients received INREBIC at 400 mg daily (n=96) or placebo (n=95). Among patients receiving INREBIC, 82% were exposed for more than 6 months and 65% for more than one year. Patients had a median duration of exposure to INREBIC 400 mg daily of 15.5 months compared with placebo where patients were treated for 6 months or until disease progression after which patients were allowed to crossover to active treatment.

The median age of patients who received INREBIC was 65 years (range: 27 to 86 years), 59% were male, 90% were White, 8% were Asian, 1% were Black, 1% were Other, and 92% had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Serious adverse reactions occurred in 21% of INREBIC-treated patients. Serious adverse reactions in ≥2% of patients receiving INREBIC 400 mg daily included cardiac failure (5%) and anemia (2%).

Fatal adverse reactions of cardiogenic shock occurred in 1% of patients receiving INREBIC 400 mg daily. Permanent discontinuation due to an adverse reaction occurred in 14% of patients receiving INREBIC. Most frequent reasons for permanent discontinuation in ≥2% of patients receiving INREBIC included cardiac failure (3%), thrombocytopenia, myocardial ischemia, diarrhea, and increased blood creatinine (2% each). Dosage interruptions due to an adverse reaction during the randomized treatment period occurred in 21% of patients who received INREBIC.

Adverse reactions requiring dosage interruption in >3% of patients who received INREBIC included diarrhea and nausea. Dosage reductions due to an adverse reaction during the randomized treatment period occurred in 19% of patients who received INREBIC. Adverse reactions requiring dosage reduction in >2% of patients who received INREBIC included anemia (6%), diarrhea (3%), vomiting (3%), and thrombocytopenia (2%). The most common adverse reactions (reported in ≥20%) were diarrhea, nausea, anemia, and vomiting.

Tables 3 and 4 summarize the common adverse reactions and laboratory abnormalities, respectively, in JAKARTA during randomized treatment. Table 3: Adverse Reactions Reported in ≥5% Patients Receiving INREBIC 400 mg with a Difference between Arms of >5% during Randomized Treatment a CTCAE version 4.03. b Only 1 Grade 4 event (anemia). c Includes cystitis. Adverse Reaction a INREBIC 400 mg (n=96) Placebo (n=95) All Grades % Grade ≥3 b % All Grades % Grade ≥3 % Diarrhea 66 5 16 0 Nausea 62 0 15 0 Anemia 40 30 14 7 Vomiting 39 3.1 5 0 Fatigue or asthenia 19 5 16

1.1 Muscle spasms 12 0 1.1 0 Blood creatinine increased 10 1 1.1 0 Pain in extremity 10 0 4.2 0 Alanine aminotransferase Increased 9 0 1.1 0 Headache 9 0 1.1 0 Weight increased 9 0 4.2 0 Dizziness 8 0 3.2 0 Bone pain 8 0 2.1 0 Urinary tract infection c 6 0 1.1 0 Dysuria 6 0 0 0 Aspartate aminotransferase increased 5 0 1.1 0 Clinically significant adverse reactions reported in 5% or less of patients: hypertension of all grades was reported in 4.2% of patients and Grade 3 or higher in 3% of INREBIC-treated patients.

Changes in selected postbaseline laboratory values that were observed are shown in Table 4 for the JAKARTA trial during randomized treatment. Table 4: Selected Laboratory Abnormalities That Have Worsened from Baseline (≥20%) in Patients Receiving INREBIC with a Difference between Arms of >10% When Compared to Placebo in JAKARTA during Randomized Treatment INREBIC 400 mg (n=96) Placebo (n=95) Laboratory Parameter All Grades % Grade ≥3 % All Grades % Grade ≥3 % Hematology Anemia 74 34 32 10 Thrombocytopenia 47 12 26 10 Neutropenia 23 5 13

3.3Biochemistry

Creatinine increased 59 3.1 19

1.1 ALT increased 43 1 14 0 AST increased 40 0 16

1.1 Lipase increased 35 10 7

2.2 Hyponatremia 26 5 11

4.3 Amylase increased 24 2.1 5 0 In FEDR-MF-002, a randomized controlled post-marketing study of INREBIC (n=134) vs. best available therapy (BAT, n=67), the incidence of thiamine levels below the lower limit of normal (< 70 nmol/L) was 21% for INREBIC vs 5% for BAT. Thiamine levels < 30 nmol/L were not observed in the study. The median time to the first low thiamine level after initiation of INREBIC was 30 days. The frequency of low thiamine levels in participants receiving INREBIC was 2% in those receiving thiamine supplementation 100 mg orally per day vs. 39% in those not receiving thiamine supplementation.

6.2Postmarketing Experience

The following adverse reactions have been identified during post approval use of INREBIC. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Eye Disorders: Uveitis

Inrebic

Indicaciones

Contraindicaciones

Advertencias y precauciones

5.1Encephalopathy, Including Wernicke's Serious

¿Dos medicamentos en una misma pregunta?

Inrebic

Indicaciones

Contraindicaciones

Advertencias y precauciones

5.1Encephalopathy, Including Wernicke's Serious

¿Dos medicamentos en una misma pregunta?

5.2Anemia and Thrombocytopenia Treatment with

5.3Gastrointestinal Toxicity

5.4Hepatic Toxicity Elevations of ALT and AST

5.5Amylase and Lipase Elevation Grade 3

5.6Uveitis

5.7Major Adverse Cardiac Events (MACE) Another Janus Kinase

Interacciones

7.1Effect of Other Drugs on

7.2Effect of

Embarazo y lactancia

8.1Pregnancy Risk Summary

Reacciones adversas

6.1Clinical Trials Experience

3.3Biochemistry

6.2Postmarketing Experience

En otros países

Presentaciones

Documentos

Fuentes y licencias

De un vistazo